Gene Expression Atlas home | about the project | faq | feedback | blog | das | api | help
CARS
REST API REST API
Homo sapiens
CARS is differentially expressed in 312 experiments: 145 organism parts: bone marrow, hypothalamus, ... (143 more);, 195 disease states: normal, control, ... (193 more);, 94 cell types 387 cell lines 46 compound treatments and 75 other conditions.
Synonyms CARS1
Orthologs A4FUC8_BOVIN (Bos taurus)   cars (Danio rerio)   ENSCING00000015319 (Ciona intestinalis)   SYCC_CHICK (Gallus gallus)   YNL247W (Saccharomyces cerevisiae)   Cars (Mus musculus)   ENSCING00000017451 (Ciona intestinalis)   Cars (Rattus norvegicus)   F6VII8_CIOIN (Ciona intestinalis)   Aats-cys (Drosophila melanogaster)   cars (Xenopus laevis)   CARS (Canis familiaris)   (Compare orthologs)
Gene Ontology Term tRNA aminoacylation for protein translation, cytosol, ligase activity, protein binding, cytoplasm, cysteinyl-tRNA aminoacylation, metal ion binding, cysteine-tRNA ligase activity, ATP binding, aminoacyl-tRNA ligase activity, nucleotide binding, protein homodimerization activity, tRNA binding, gene expression
InterPro Term aa-tRNA-synt_I, Cys-tRNA-synt_Ia
UniProt Accession Q5HYE4, A8MVQ3, P49589, C9JLN0, B4DI19, B4DKY1, E9PPK8, E9PRS8, E9PLP0
Search EB-eye ENSG00000110619
Show more properties
Experimental Factors
Organism part

studied in E-GEOD-15765, E-GEOD-6573, E-GEOD-7540, E-GEOD-3526, E-MTAB-62, ... (29 experiments)

3
1
Number of published studies where the gene is over/under expressed compared to the gene's overall mean expression level in the study.

anatomogram

Cell line

studied in E-GEOD-5258, E-GEOD-4525, E-GEOD-19639, E-GEOD-2450, E-MTAB-62, ... (36 experiments)

Factor Value U/D Experiments
HL-60
4
E-GEOD-5258, E-MTAB-37, E-GEOD-24147, E-GEOD-96
MCF-7
3
E-GEOD-20081, E-GEOD-3529, E-GEOD-19639
SW480
3
E-MEXP-1014, E-MTAB-37, E-GEOD-2509
HCC1937
2
E-MTAB-37, E-MTAB-62
MDA-MB-231
2
E-TABM-420, E-MTAB-62
MOLT4
2
E-MTAB-37, E-MTAB-62
381 more value(s).


Cell type

studied in E-TABM-40, E-GEOD-21668, E-GEOD-3920, E-MEXP-66, E-GEOD-4219, ... (48 experiments)

Factor Value U/D Experiments
fibroblast
3
E-GEOD-3920, E-GEOD-3204, E-GEOD-26672
721 B lymphoblast
1
2
E-AFMX-5, E-TABM-145
1
2
E-TABM-145, E-TABM-130
stromal cell
1
2
E-GEOD-1460, E-GEOD-3998, E-GEOD-10797
primary fibroblast
1
E-MEXP-66
mononuclear cell
1
E-GEOD-6053
88 more value(s).


Disease state

studied in E-GEOD-3307, E-GEOD-15960, E-GEOD-2466, E-TABM-15, E-GEOD-16363, ... (62 experiments)

Factor Value U/D Experiments
lung adenocarcinoma
3
E-MTAB-37, E-MTAB-62, E-GEOD-2514
dermatomyositis
2
E-GEOD-5370, E-GEOD-1551
acute promyelocytic leukemia
2
E-MTAB-62, E-GEOD-995
colon carcinoma
2
E-GEOD-3726, E-MTAB-37
multiple myeloma
2
E-MTAB-62, E-GEOD-6691
uterine fibroid
2
E-MTAB-62, E-GEOD-7307
189 more value(s).


Compound treatment

studied in E-GEOD-5258, E-GEOD-697, E-TABM-782, E-GEOD-5824, E-MEXP-1958, ... (27 experiments)

Factor Value U/D Experiments
2,3-dimethoxy-1,4-naphthoquinone
1
E-GEOD-6907
HMB-PP (phosphoantigen)
1
E-MEXP-1601
ZMYM2/FGFR1
1
E-GEOD-15811
unknown
1
E-GEOD-7307
4-hydroxytamoxifen
2
1
E-MEXP-2241
ethanol
1
E-MEXP-2241
40 more value(s).


Agent

studied in E-GEOD-19519

Factor Value U/D Experiments
DMSO
1
E-GEOD-19519
tunicamycin
1
E-GEOD-19519
thapsigargin
1
E-GEOD-19519


Biosource provider
studied in E-TABM-325, E-MTAB-37, E-GEOD-14359, E-GEOD-20559

BioSourceProvider
studied in E-GEOD-19466, E-GEOD-19480

Blood/non-blood meta-groups
studied in E-MTAB-62

Bmngrd
studied in E-GEOD-20194, E-GEOD-16716

Cancer site
studied in E-GEOD-4271

Cellular component
studied in E-GEOD-1400

Clinical history
studied in E-GEOD-19420, E-TABM-234, E-GEOD-19743, E-GEOD-7967, E-GEOD-21374, ... (7 experiments)

Clinical info
studied in E-GEOD-19743, E-MTAB-37, E-MEXP-1251, E-GEOD-21374, E-GEOD-1563, ... (8 experiments)

Clinical treatment
studied in E-GEOD-6532

Developmental stage
studied in E-GEOD-19743, E-GEOD-20033, E-GEOD-3140, E-MEXP-2359, E-GEOD-6236, ... (8 experiments)

Disease staging
studied in E-GEOD-1323, E-GEOD-19743, E-GEOD-3325, E-GEOD-2509, E-TABM-147, ... (9 experiments)

Environmental stress
studied in E-GEOD-1643, E-GEOD-1518

Er
studied in E-GEOD-20194, E-GEOD-16716

Estrogen receptor status
studied in E-GEOD-6532

Ethnic group
studied in E-GEOD-20194, E-GEOD-16716

Ethnicity
studied in E-GEOD-16363

family id
studied in E-GEOD-19519

Genetic modification
studied in E-GEOD-8023, E-MTAB-73, E-GEOD-4025, E-GEOD-7578, E-GEOD-17385, ... (9 experiments)

Genotype
studied in E-GEOD-2466, E-GEOD-17476, E-GEOD-21750, E-MEXP-421, E-GEOD-22593, ... (11 experiments)

Gestation age
studied in E-GEOD-14334

369 groups
studied in E-MTAB-62

4 groups from blood to incompletely diff
studied in E-MTAB-62

96 groups
studied in E-MTAB-62

Growth condition
studied in E-MEXP-2657, E-GEOD-20540, E-MEXP-1273, E-GEOD-20505, E-MEXP-1220, ... (13 experiments)

Her2 fish
studied in E-GEOD-20194, E-GEOD-16716

Her2 ihc
studied in E-GEOD-20194, E-GEOD-16716

Histology
studied in E-TABM-234, E-TABM-276, E-GEOD-2748

Individual
studied in E-TABM-325, E-MTAB-197, E-MEXP-2069, E-GEOD-1926, E-GEOD-10433, ... (36 experiments)

Infection
studied in E-GEOD-12108, E-GEOD-6802, E-GEOD-360

Injury
studied in E-GEOD-19743

Ki67 ihc
studied in E-GEOD-21653

Labeling
studied in E-LGCL-5

Light
studied in E-GEOD-1725

Lymph node status
studied in E-GEOD-6532

Material type
studied in E-MEXP-455

Media
studied in E-MEXP-765

15 meta groups
studied in E-MTAB-62

4 meta groups
studied in E-MTAB-62

6 meta groups
studied in E-MTAB-62

Metastasis
studied in E-GEOD-18105

Molecular subtype
studied in E-GEOD-21653

Nbefore
studied in E-GEOD-20194, E-GEOD-16716

Observation
studied in E-TABM-276

organ
studied in E-GEOD-24283

Organism
studied in E-GEOD-7540, E-TABM-84

Organism status
studied in E-GEOD-19188

Original diagnosis
studied in E-GEOD-21521

Performer
studied in E-LGCL-5

Phenotype
studied in E-GEOD-7819, E-GEOD-26495, E-GEOD-19703, E-GEOD-21750, E-GEOD-1657, ... (7 experiments)

Population
studied in E-GEOD-4922, E-GEOD-4342

Progesterone receptor status
studied in E-GEOD-3494, E-GEOD-6532

Protocol type
studied in E-GEOD-22097, E-GEOD-3254, E-GEOD-21837, E-GEOD-19445, E-GEOD-19246, ... (6 experiments)

pt
studied in E-GEOD-21653

Replicate
studied in E-GEOD-18791

Rna integrity
studied in E-TABM-325

RNAi
studied in E-MEXP-2115, E-GEOD-1703, E-GEOD-12438, E-GEOD-1676, E-MEXP-101, ... (8 experiments)

Sample preparation
studied in E-GEOD-16728

sampleID
studied in E-GEOD-24283

Sampling time point
studied in E-GEOD-16797, E-GEOD-19743, E-MEXP-70, E-GEOD-17400

Sex
studied in E-GEOD-1643, E-GEOD-19069, E-GEOD-2466, E-GEOD-7307, E-GEOD-16363 ... (5 experiments)

Stimulation
studied in E-GEOD-4883, E-GEOD-11886, E-GEOD-11428

stimulus
studied in E-GEOD-22103

Strain or line
studied in E-MEXP-1996, E-TABM-125

Subtype
studied in E-GEOD-24283

Survival time
studied in E-GEOD-19188

targeted_cell_type
studied in E-MEXP-70

Tbefore
studied in E-GEOD-20194, E-GEOD-16716

Test result
studied in E-TABM-276, E-GEOD-2748

Transfection
studied in E-GEOD-14680

Treatment
studied in E-GEOD-22369, E-GEOD-22368, E-GEOD-16837, E-GEOD-21909, E-GEOD-19246, ... (9 experiments)

Treatment code
studied in E-GEOD-20194, E-GEOD-16716

Treatments comments
studied in E-GEOD-20194, E-GEOD-16716

Tumor grading
studied in E-GEOD-4290, E-GEOD-4271, E-GEOD-3494, E-GEOD-4922

Vehicle
studied in E-GEOD-5258

Processing time: 0.37 secs.
 
Gene Expression Atlas 2.0.11.1- 12/23/11 3:09:34 PM